Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Late Effects Testicular Germ Cell Tumor Mixed Non-Metastatic Breast Carcinoma Soft Tissue Sarcoma, Adult, Stage IIC Osteosarcoma Ewing's Sarcoma Acute Myeloid Leukemia Hodgkin Disease Non Hodgkin Lymphoma Age ≥ 18 years old and ≤ 65 years old. 2. Follow-up at the Léon Bérard center 3. Treated by chemotherapy for one of the following pathologies, and confirmed by the reference diagnostic technique  acute myeloid leukemia Hodgkin's lymphoma aggressive non-Hodgkin's lymphoma primary non-metastatic invasive breast carcinoma testicular germ cell tumor treated with at least 3 courses of BEP (bleomycin, etoposide, cisplatin), 4 courses of EP (etoposide, cisplatin) or 4 courses of VIP (etoposide, ifosfamide, cisplatin) received high-grade soft tissue sarcoma, osteosarcoma or Ewing's sarcoma. 4. As a complete response at the end of treatment consultation. If end-of-treatment evaluation is not available at the time of as an assumed complete response in the opinion of the investigator based on the previous assessment of response. 5. Whose capacity to practice an adapted physical activity will have been certified by a medical certificate issued by the investigating physician, the general practitioner or the referring physician. 6. Able to understand, read and write French. 7. Available and willing to participate in the project throughout the duration of the study. 8. Living in the Auvergne-Rhône-Alpes region or in the department of Saône-et-Loire 9. Affiliated with a health insurance plan. 10. Having declared an attending physician. 11. Having signed and dated the informed consent  With a history of malignancy other than basal cell skin cancer. 2. Cannot be followed for medical, social, family, geographical or psychological reasons for the duration of the study. 3. Participating in other studies that could impact on the evaluation of the judgement criteria. 4. Deprived of liberty by judicial or administrative decision